Sep 17, 2021 01:27 PM IST
Apart from securing the support of ASEAN nations for the global intellectual property waiver for COVID vaccines, the move is also aimed at pulling closer the traditional partners in the bloc, who have become close to China, sources say
- Jul 31, 2021 01:27 PM IST
His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."
- Jan 03, 2020 07:33 PM IST
Moneycontrol’s Shraddha Sharma talks to Viswanath Pilla to know more about the debate and if there are solutions to it.
- May 15, 2019 09:45 PM IST
Lupin was named as a defendant with respect to 11 generic drugs for alleged price manipulation.
- Mar 08, 2019 08:10 AM IST
Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk
- Mar 07, 2019 08:07 AM IST
The US FDA has been driving generic drug approvals under its current commissioner. His resignation raises a question mark on whether life could change for Indian pharmaceutical companies
- Apr 24, 2017 06:08 PM IST
MSF said the unhealthy nexus between doctors and pharma companies encourages over prescription of expensive medicines.
- Apr 18, 2017 09:59 PM IST
- Apr 10, 2017 04:28 PM IST
As global drug makers are exiting low priority brands, their Indian counterparts are lapping up the opportunity buying established products at perhaps low valuations.
- Feb 23, 2017 10:00 PM IST
There's no end in sight for the Indian pharmaceutical industry's struggles with domestic and foreign drug regulators. It's true that quite a few companies have received clean chits from regulators in the US, UK and Europe. However, at the same time, new issues have also been cropping up with disturbing frequency.
- Jan 14, 2017 02:00 PM IST
Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years
- Dec 28, 2016 11:04 AM IST
HYDERABAD (Reuters) - Vasudeva Prakash left his job as a mechanic in Hyderabad three years ago for what he calls a more lucrative career: taking part in clinical trials on generic drugs.
- Nov 21, 2016 09:42 PM IST
Appaji said the country exports its one-third pharma products to US alone. "But we are looking at more opportunities in Japan and Latin American markets," he said.
- Nov 07, 2016 07:58 PM IST
A Democrat sweep in US polls may
pose even greater pricing challenges for the pharma industry
and pave the way for tighter pricing regulations for both
brand name and generic drugs, according to a report.
- Jun 08, 2016 10:09 PM IST
Over the last year, regulatory hassles have made US market tougher to navigate for Indian companies. Sun Pharmaceutical MD Dilip Shanghvi, however, says this is the time to dig in, and do more to maintain ownership of that market.
- Apr 15, 2016 06:50 PM IST
Major domestic firms such as Sun Pharma, Lupin, Glenmark, Aurobindo, Alembic and Hetero Labs figure in the list of first-time generic drug approvals released by the FDA's Office of Generic Drugs.
- Aug 20, 2015 08:19 AM IST
India, on Wednesday, expressed concern over EU's ban on medicines clinically tested by GVK Biosciences, saying it could lead to 'adverse campaign' about clinical trials done in the country.
- May 21, 2015 01:02 PM IST
The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.
- Nov 12, 2014 08:34 AM IST
India's USD 15 billion pharmaceutical industry, which has been hit by a spate of regulatory sanctions in the past year due to concerns about production processes, supplies about 40 percent of generic and over-the-counter drugs to the United States.
- Aug 22, 2013 10:28 PM IST
Leading pharma player Cipla said it has targeted a revenue of USD 5 billion by 2020, of which USD 1 billion will come from the US market.
- Aug 22, 2013 02:14 PM IST
According to the US FDA, Dr Reddy's initiated recall of the antacid in 150mg strength voluntarily.
- Aug 12, 2013 11:26 AM IST
Sun Pharma wrote-off Rs 2,517 crore to settle a patent litigation with Pfizer, which resulted in a consolidated Q1 net loss of Rs 1,276 crore. However, adjusted profit jumped 56 percent and revenue was up 32 percent, sending the stock up over 8 percent.
- Aug 08, 2013 06:24 PM IST
Sun Pharma's revenue is expected to rise 23 percent year-on-year to Rs 3,287 crore, driven by over 20 percent growth in US sales. Domestic formulations sales are, however, likely to be lower due to the impact of the new drug pricing policy.
- Jul 30, 2013 03:36 PM IST
The generic drugs maker's revenue in April-June also missed analysts expectations, growing 12 percent to Rs 2,845 crore. Growth was particularly hurt by a decline in generic drugs sales in Europe and slow growth in Russia. India generics business growth was also flat.
- Jul 29, 2013 06:17 PM IST
The generic drugs maker's earnings will be boosted by strong growth in the US and Russian generics drugs market and better currency realisations.